0913693 B.C. Ltd (REPCF)

Replicel Life Sciences Inc was incorporated under the Ontario Business Corporations Act on April 24, 1967. The Company is a clinical stage biopharmaceutical company engaged in developing autologous cell therapies that treat functional cellular deficits. RepliCel Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon injuries. Initiation of Phase 2 trials are planned for 2014 on RepliCel's RCT-01 treatment for Achilles tendinosis and RCH-01 treatment for androgenetic alopecia. Shiseido Company, Limited has geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. Both product candidates are based on RepliCel's technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. These products are built on the company's proprietary manufacturing platforms. The Company is also developing a unique programmable cell injector device designed for dermal injections. In addition to addressing the delivery requirements for RCT-01 and RCH-01, this device should have applications in many current dermatological injection procedures with the added benefit of physician controlled programmable depth and volumes.